Hyaluronidase

DB14740ApprovedInvestigationalProtein Based TherapiesGlycoside Hydrolases

Hyaluronidase is an enzyme used to improve the absorption and dispersion of parenterally administered fluids, drugs, and contrast agents. The action of hyaluronidase was first described in 1936, and named in 1939.

Mechanism
Curator reviewed · 5 references
Primary indication
Hyaluronidase is indicated for subcutaneous fluid administration for hydration, and increasing resorption of radiopaque agents in subcutaneous urography.Curator reviewed · 3 structured indications
First approval
Canada, 1954 · United States, 2004
Also known as
Hyaluronidase (bovine) · Hyaluronidase bovine · Hyaluronidase, bovine · Hyaluronoglucosaminidase
Brand names
  • Amphadase

Resolves to

What you can answer from here — as of January 09, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
196Drug interactionsStructured to mechanism, not free text
Sign in
83Clinical trialsPhase, status and sponsor resolved per trial
Sign in
3Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
1ContraindicationEach with its own population and attribute set
Sign in
11Marketed productsAcross 6 countries and 10 labellers
Sign in
1ATC codeIncluding every combination product, plus 9 drug categories
Sign in
15+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Hyaluronidase, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account